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ABSTRACT
Background and Objectives: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, 
and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have 
been conducted with different ARBs. We compared these effects in patients with uncomplicated hypertension who were re-
ceiving telmisartan or valsartan. Subjects and Methods: The subjects were patients with essential hypertension (48.4±9.6 
years) who were randomly assigned to take either telmisartan (80 mg/day, n=30) or valsartan (160 mg/day, n=30) for 12 
weeks. Their anthropometric, laboratory, vascular, and echocardiographic data were measured at baseline and at the end of 
the study. Results: Baseline characteristics were not significantly different between the two groups, except for the carotid-
femoral pulse wave velocity (cfPWV; telmisartan group vs. valsartan group; 841.2±131.0 vs. 761.1±104.4 cm/s, p<0.05). Af-
ter 12 weeks, BP had fallen to a similar extent with mean reductions in the systolic and diastolic BP of 20.7±18.1 and 
16.3±13.0 mm Hg (p<0.001, respectively) for the telmisartan and 22.5±17.0 and 16.8±9.3 mm Hg (p<0.001, respectively) for 
the valsartan group. Although the cfPWV and left ventricular mass index (LVMI) fell significantly only with the administra-
tion of telmisartan, they were not significantly different when baseline cfPWV was considered. The differences in the cfPWV 
and LVMI changes from baseline between the two groups were also not significant after adjusting for baseline cfPWV. No sig-
nificant changes in other vascular, metabolic, or inflammatory parameters were observed with either treatment. Conclusion: 
The effects of a 12-week treatment with the two ARBs, telmisartan and valsartan, on cardiovascular, metabolic, and inflam-
matory parameters were not different in patients with uncomplicated hypertension. (Korean Circ J 2011;41:583-589)
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Introduction
The renin-angiotensin system (RAS) is one of the most im-
portant mechanisms implicated in the development of car-
diovascular disease. The pathophysiological effects of angio-
tensin II, the key player in the RAS, that potentially lead to 
cardiovascular disease include vasoconstriction, endothelial 
dysfunction, increased thrombosis, superoxide production, 
vascular smooth muscle growth, myocyte hypertrophy, fi-
brosis, remodeling of tissues, and stimulation of a number of 
inflammatory and hormonal mediators.
1)
Angiotensin-receptor blockers (ARBs) are the most recent-
ly approved class of antihypertensive agents that inhibit the 
RAS by selectively blocking the AT-1 receptor, so ARBs inhi-
bit most of the deleterious effects of angiotensin II. In addi-
tion to blood pressure (BP) control, ARBs may have beneficial 
effects on left ventricular hypertrophy, arterial stiffness, vas-
cular endothelial function, and carotid intima-media thick-
ness (IMT), all of which are well-known surrogate markers 
and intermediate endpoints for cardiovascular morbidity and 
mortality.
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Further, RAS blockers, including angiotensin-converting 
enzyme inhibitors (ACEIs) and ARBs, reduce the incidence of 
new-onset diabetes.
4)5) Recent in vitro and animal studies have 
suggested that some ARBs act as partial peroxisome prolif-
erator-activated receptor-gamma (PPARγ) agonists and that 
this does not depend on an AT-1 receptor blockade; thus, this 
may improve insulin sensitivity and the lipid profile.
6)7)
Inflammation is one of the plausible mechanisms by whi-
ch angiotensin II accelerates the development of atheroscle-
rosis
8) and evidence exists that inflammatory markers are re-
duced by ARBs independent of changes in BP.
9)10)
The cardiovascular, metabolic, and anti-inflammatory ef-
fects of ARBs are thought to be similar and rarely compared 
within the drug class, though important structural differences 
exist among the various compounds. The purpose of this 
study was to compare these cardiovascular, metabolic, and 
anti-inflammatory effects between telmisartan and valsartan 
in uncomplicated hypertensive subjects. 
Subject and Methods
Subjects
We performed a prospective, randomized, open-label, fix-
ed-monotherapy, single center, parallel-group study. Patients 
were recruited from the Cardiovascular Center at Korea Uni-
versity Guro Hospital, Seoul, Korea. Inclusion criteria were 
newly diagnosed or known hypertensive subjects who were 
not taking antihypertensive agents for more than the last 4 
weeks. Patients with the following conditions were excluded; 
1) hyperkalemia >5.5 mmol/L, 2) serum creatinine >2 mg/
dL, 3) hemoglobin A1c (HbA1c) >8.0%, 4) secondary hyper-
tension, 5) hormone therapy or steroid administration, 6) 
taking antidiabetic or lipid-lowering agents, 7) known coro-
nary artery disease or significant atherosclerotic disease of 
other vessels and, 8) clinically significant nervous, gastrointe-
stinal disease, or malignant disease. All subjects gave their writ-
ten informed consent, and the Korea University institutional re-
view board approved the study protocol in accordance with 
the Declaration of Helsinki of the World Medical Association.
After a 2-week run-in period, patients were randomized to 
receive either telmisartan (80 mg/day; n=30) or valsartan (160 
mg/day; n=30) for a 12-week open-labeled phase. Patients 
were requested to take their study medication with water in 
the morning and at approximately the same time each day. 
Patients were seen on the screening visit, 1 week before ran-
domization (baseline laboratory and cardiovascular studies), 
at entry (randomization), and at 4 and 12 weeks of treatment. 
At week 12, physical examinations, laboratory assessments, 
and cardiovascular studies were repeated.
Blood pressure measurement
After at least 10 minutes of rest, sitting systolic and diastolic 
BPs were recorded twice every 2 minutes by a research nurse 
using a random zero mercury sphygmomanometer fitted with 
an appropriate cuff size. The recorded BPs were averaged for 
use in the analysis. Patients in which systolic pressure was 
>140 mm Hg or diastolic pressure was >90 mm Hg were de-
fined as having hypertension.
Anthropometric and laboratory measurements
Age, gender, body weight, waist circumference, and body 
mass index (BMI) were recorded. Waist circumference was 
measured at the midpoint between the lower border of the rib 
edge and the iliac crest, and BMI was calculated as the weight/ 
height
2 (kg/m
2). Current smoking was defined as active smok-
ing within the past 12 months. All blood samples were obta-
ined in the morning with subjects in a fasting state. Insulin 
resistance was calculated by the Homeostasis Model of As-
sessment (HOMA).
11) HbA1c was measured using high per-
formance liquid chromatography (Bio-Rad Variant II, Her-
cules, CA, USA). Serum adiponectin and interleukin-6 levels 
were measured using an enzyme-linked immunosorbent as-
say (Samkwang Medical Laboratories, Seoul, Korea). 
Measurement of pulse wave velocity
All procedures were conducted in a controlled environ-
ment by an experienced technician who was blinded to the 
clinical information. The carotid-femoral pulse wave velocity 
(cfPWV) was determined using the PP-1000 semiautomatic 
device (Hanbyul Meditech, Seoul, Korea).
12) Briefly, the left 
common carotid artery (CCA), radial artery, femoral artery, 
and dorsal artery pressure waveforms were recorded non-in-
vasively using a tonometric pressure sensor. An electrocar-
diogram, phonocardiogram and four-channel pressure wave-
forms were simultaneously measured. The distance (D) tra-
veled by the pulse wave was automatically obtained from the 
age- and height-based distance of the upper and lower extre-
mity arteries of Koreans, and this was provided by the Korea 
Research Institute of Standards and Science. The pulse tran-
sit time (t), which was measured between the feet of the pres-
sure waveforms that were recorded at two different recording 
points (the foot-to-foot method), was automatically deter-
mined. The PWV was automatically calculated as D/t. Am-
ong the carotid-femoral, carotid-radial, and femoral-dorsal 
PWVs, we only used the cfPWV in the current study because 
it is the most clinically relevant index.
13) Pearson’s correlation 
coefficient for intraobserver reproducibility was 0.99 (p< 
0.001). In the Bland-Altman plot of intraobserver measure-
ment, the mean difference in the repeated measurements was 
-0.056±0.223, and most of the values ranged within a mean± 
1.96 SD.
Measurement of the carotid intima medial thickness
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an 11-MHz linear-array transducer that was connected to a 
Vivid-7 echocardiograph (General Electronics Corp., Hor-
ten, Norway). The right and left CCA intima-media thick-
ness (IMT) were measured at least 10 mm proximal to the 
bifurcation. Maximum and mean IMT values were automa-
tically calculated using programmed software (M’ATH, ME-
TRIS Co., Argenteuil, France). 
Measurement of flow-mediated dilation
We tested the function of vascular endothelial cells using 
flow-mediated dilation (FMD). FMD was assessed using bra-
chial artery two-dimensional ultrasonography (Vivid-7, Gene-
ral Electronics Corp., Horten, Norway) using a modification 
of the method of Corretti et al.
14) Measurements were perform-
ed on the left arm with subjects in the supine position after a 
10-20 minute rest in a quiet dark room at a temperature of 
22°C. The brachial artery was scanned longitudinally, just 
above the antecubital crease, using an 11-MHz probe. Hype-
remia was induced by inflating a pneumatic cuff to 230 to 250 
mm Hg for 5 minutes on the middle of the forearm; the maxi-
mum arterial diameter was then measured 45-60 seconds af-
ter sudden deflation of the cuff. The maximum diameter dur-
ing hyperemia compared with the baseline diameter was used 
for analysis. We measured each diameter three times during 
two beats, and the mean data were used for the final analy-
sis. Measurements were conducted by an independent obser-
ver who remained blinded to the medication of the study. FMD 
was defined as the percent increase in the arterial diameter dur-
ing hyperemia, i.e., 100×{(diameter after hyperemia-baseline 
diameter)/baseline diameter}.
Echocardiographic measurement
Two-dimensional and guided M-mode echocardiograms 
were performed on each subject by a single sonographer and 
confirmed by an experienced cardiologist who were blinded 
to the clinical information. A commercially available mach-
ine (Vivid-7, General Electronics Corp., Horten, Norway) 
with a 1.5-4.0 MHz transducer was used. The left ventricular 
internal end-diastolic dimension, the end systolic dimension, 
and the septal and posterior wall thicknesses were measured 
on the leading edge to the leading edge, according to the 
guidelines of the American Society of Echocardiography. The 
left ventricular mass was calculated according to the formula 
of Devereux et al.
15) The left ventricular mass index (LVMI) was 
calculated as the left ventricular mass/body surface area (g/m
2). 
Statistical analysis
Data were analyzed by nonparametric methods to avoid 
assumptions about the distribution of the measured variables. 
Comparisons between groups were made using the Mann-
Whitney U-test. Differences between baseline and post-treat-
ment values were analyzed using the Wilcoxon’s signed-rank 
test. The Mann-Whitney analysis was used for comparing ch-
anges and percent changes between the baseline and post-
treatment values in patients receiving telmisartan versus those 
receiving valsartan. Differences in the changes in cfPWV and 
LVMI from baseline between the treatment groups were an-
alyzed with an analysis of covariance, in which the possible 
confounding effects of baseline cfPWV, BP change, and heart 
rate change were considered as covariates by including them 
into the model. The distributions of continuous variables in 
the groups are expressed as means±SDs. A p<0.05 was con-
sidered statistically significant. All statistical results were bas-
ed on two-sided tests. The data were analyzed using SPSS for 
Windows (Version 12.0; SPSS Inc., Chicago, IL, USA).
Results
Subject characteristics
A total of 120 patients were screened, of whom 65 were eli-
gible to enter the study. These patients were randomized to 
the telmisartan (n=33) and valsartan (n=32) groups. Three 
patients in the telmisartan group (two consented withdrawal, 
one lost to follow-up) and two patients in the valsartan group 
(one consented withdrawal, one lost to follow-up) dropped 
out of the study before obtaining a postbaseline measurement. 
This remaining 60 patients (telmisartan group=30 and val-
sartan group=30) formed the intent to treat (ITT) population, 
defined as all randomized patients who provided baseline 
and follow-up data.
The study subjects consisted of 38 men (63.3%) and 22 wo-
men (36.7%), with a mean age of 48.4±9.6 years old. The ba-
seline characteristics of the hypertensive patients are shown 
in Table 1. The clinical characteristics of the two groups were 
well matched except for the cfPWV, which was significantly 
greater in the telmisartan group than that in the valsartan 
group (841.2±131.0 cm/s vs. 761.1±104.4 cm/s, p<0.05). 
Blood pressure control
After 12 weeks of treatment, both telmisartan and valsar-
tan significantly reduced systolic (p<0.001) and diastolic BPs 
(p<0.001) compared with baseline (Table 2). The mean re-
ductions in systolic BP were 20.7±18.1 mm Hg in the telmis-
artan group and 22.5±17.0 mm Hg in the valsartan group. 
The mean reductions in diastolic BP were 16.3±13.0 mm Hg 
in the telmisartan group and 16.8±9.3 mm Hg in the valsartan 
group. No significant changes in heart rate compared with 
baseline were observed in either treatment.
Metabolic and inflammatory profile
A 12-week administration of telmisartan and valsartan did 
not result in any changes in BMI, waist circumference, HbA1c, 
fasting plasma glucose, fasting plasma insulin, HOMA, or ad-
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changes were observed compared with baseline in the lipid 
profiles of the patients who had received telmisartan or val-
sartan, but there were trends for a reduction in total choleste-
rol (-4.7%, p=0.075) and triglyceride (-5.6%, p=0.058) in the 
telmisartan group (Table 2). Interleukin-6 was not signifi-
cantly reduced in either group.
Cardiovascular indices 
After 12-weeks of telmisartan treatment, a significant re-
duction in cfPWV was observed (-7.5%, p<0.05), whereas the 
decrease in the valsartan group was not statistically significant 
(Table 2). However, the results were the reverse when baseline 
cfPWV, which was significantly higher in the telmisartan gr-
oup than in the valsartan group, was considered in the analy-
Table 1. Demographics and baseline characteristics of the hyper-
tensive patients randomized to treatments with 80 mg telmisartan 
and 160 mg valsartan for 12 weeks
Telmisartan 
group
(n=30)
Valsartan 
group
(n=30)
p
Male (%) 21 (70) 17(57) 0.422
Age (years) 048.2±10.0 48.7±9.4 0.790
BMI (kg/m
2) 25.0±2.7 25.0±2.3 0.959
Waist circumference (cm) 86.4±8.3 86.2±6.6 0.790
Smoking (%) 6 (20) 6 (20) 1.000
SBP (mm Hg) 153.2±18.9 151.7±16.2 0.549
DBP (mm Hg) 101.1±11.4 099.3±10.5 0.625
HR (bpm) 72.7±9.4 76.9±9.7 0.056
HbA1c (%) 05.8±0.7 05.6±0.4 0.445
FPG (mg/dL) 100.6±13.9 096.9±12.1 0.185
FPI (μIU/mL) 06.2±5.9 06.1±3.7 0.658
HOMA 01.6±1.6 01.5±0.9 0.750
TC (mg/dL) 193.2±34.4 198.5±31.8 0.636
TG (mg/dL) 162.5±76.5 0165.2±127.9 0.297
HDL-C (mg/dL) 049.4±12.4 052.0±13.6 0.534
LDL-C (mg/dL) 128.7±29.0 130.5±27.6 0.959
Adiponectin (ng/mL) 059.2±38.9 076.4±57.4 0.220
IL-6 (pg/mL) 01.41±1.80 01.35±1.50 0.894
cfPWV (cm/s) 0841.2±131.0 0761.1±104.4 0.041
Carotid IMT (mm) 00.73±0.17 00.67±0.13 0.158
FMD (%) 07.1±4.1 08.4±4.3 0.150
LV EF (%) 62.0±1.5 62.5±1.3 0.179
LVMI (g/m
2) 126.3±26.8 124.2±24.3 0.767
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, HR: heart rate, HbA1c: glycosylated hemoglobin, 
FPG: fasting plasma glucose, FPI: fasting plasma insulin, HOMA: 
homeostasis assessment model of insulin resistance, TC: total cho-
lesterol, TG: triglyceride, HDL-C: high density lipoprotein-choles-
terol, LDL-C: low density lipoprotein-cholesterol, IL-6: interleukin-6, 
cfPWV: carotid-femoral pulse wave velocity, IMT: intima-media th-
ickness, FMD: flow-mediated dilation, LVEF: left ventricular ejec-
tion fraction, LVMI: left ventricular mass index
Table 2. Effects of administering 80 mg telmisartan and 160 mg 
valsartan for 12 weeks in patients with hypertension
Characteristics
Telmisartan 
group 
Valsartan 
group  p
(n=30)  (n=30)
SBP (mm Hg) 0.425
Baseline 153.2±18.9 151.7±16.10
Study end 133.3±15.5 129.2±15.10
p <0.001 <0.001
DBP (mm Hg) 0.329
Baseline 101.1±11.4 99.3±10.5
Study end  84.8±9.8 82.4±11.3
p <0.001 <0.001
BMI (kg/m
2) 0.657
Baseline 25.0±2.7 25.0±2.30
Study end  25.0±2.8 24.8±2.10
p 0.932 0.131
Waist (cm) 0.695
Baseline 86.4±8.3 86.2±6.60
Study end  86.0±7.9 85.8±6.30
p 0.201 0.097
HbA1c (%) 0.285
Baseline 05.8±0.7 5.6±0.4
Study end  05.7±0.6 5.5±0.4
p 0.852 0.641
FPG (mg/dL) 0.112
Baseline 100.6±13.9 96.9±12.1
Study end  100.4±13.5 94.8±9.70
p 0.983 0.578
FPI (μIU/mL) 0.906
Baseline 06.2±5.9 6.1±3.7
Study end  08.0±5.5 7.6±4.4
p 0.098 0.139
HOMA 0.679
Baseline 01.6±1.6 1.5±0.9
Study end  02.0±1.4 1.8±1.1
p 0.133 0.206
TC (mg/dL) 0.060
Baseline 193.2±34.4 198.5±31.80
Study end  182.2±33.1 198.5±30.70
p 0.075 0.902
TG (mg/dL) 0.813
Baseline 162.5±76.5 165.2±127.9
Study end  140.3±67.2 168.3±148.6
p 0.058 0.544
HDL-C (mg/dL) 0.178
Baseline 049.4±12.4 52.0±13.6
Study end  048.5±11.7 51.6±11.0Sung Yoon Lim, et al.   587
sis. The adjusted mean {95% confidence interval (CI)} chan-
ge in cfPWV from baseline was -41.8 (-87.4, 3.7) cm/s in the 
telmisartan group and -77.8 (-123.3, -32.3) cm/s in the val-
sartan group (Fig. 1). The carotid IMT and FMD did not sig-
nificantly change in either group compared with baseline, 
although there was a trend for a reduction in the carotid IMT 
(-3.7%, p=0.061) in the telmisartan group (Table 2). Contr-
ary to the slight non-significant progression (8.7%, p=0.781) 
of the LVMI for those patients who received valsartan, a sig-
nificant regression in the LVMI (-5.9%, p<0.02) was observ-
ed in the telmisartan group at the end of the study (Table 2). 
But, the change in the LVMI was not significant in either gr-
oup after adjusting for baseline cfPWV. The adjusted mean 
(95% CI) change in LVMI from baseline was -10.9 (-24.5, 2.6) 
g/m
2 in the telmisartan group and 7.7 (-5.8, 21.3) g/m
2 in the 
valsartan group (Fig. 2).
Differences in the changes of the study variables 
from baseline to the end of the study 
When we compared changes between baseline and the post-
treatment values in patients receiving telmisartan versus those 
receiving valsartan, no significant differences were observed 
for any of the anthropometric, hemodynamic, metabolic, or 
cardiovascular variables including the cfPWV (-80.5±189.2 
cm/s vs. -39.1±138.6 cm/s, p=0.399), but a significant differ-
ence was observed for the LVMI. The mean changes in the 
LVMI were -9.6±22.7 g/m
2 for the telmisartan group versus 
6.4±45.3 g/m
2 for the valsartan group (p<0.05). However, the 
mean (95% CI) differences (telmisartan group-valsartan gr-
oup) in the changes of cfPWV and LVMI were 36.0 (-30.2, 
102.2) cm/s (p=0.281) and -18.7 (-38.3, 1.0) g/m
2 (p=0.063), 
Fig. 1. Adjusted changes from baseline and between treatment dif-
ferences in mean cfPWV in patients with hypertension randomiz-
ed to telmisartan () or valsartan () for 12 weeks.  Adjusted be-
tween treatment difference (telmisartan-valsartan). Error bars show 
95% confidence intervals. *p<0.05. cfPWV: carotid-femoral pulse 
wave velocity.
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Fig. 2. Adjusted changes from baseline and between treatment dif-
ference in mean LVMI in patients with hypertension randomized to 
telmisartan () or valsartan () for 12 weeks.  Adjusted between 
treatment difference (telmisartan-valsartan). Error bars show 95% 
confidence intervals. LVMI: left ventricular mass index.
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Table 2. Continued
Characteristics
Telmisartan 
group 
Valsartan 
group  p
(n=30)  (n=30)
p 0.394 0.544
LDL-C (mg/dL) 0.290
Baseline 128.7±29.00 130.5±27.60
Study end  123.5±29.20 131.1±22.40
p 0.375 0.900
Adiponectin (ng/mL) 0.182
Baseline 59.2±38.9 76.4±57.4
Study end  60.2±32.3 80.9±60.3
p 0.858 0.541
IL-6 (pg/mL) 0.249
Baseline 1.41±1.80 1.35±1.50
Study end  1.19±1.49 1.15±0.89
p 0.452 0.620
cfPWV (cm/s) 0.252
Baseline 841.2±131.0 761.1±104.4
Study end  760.7±136.8 722.0±100.6
p 0.023 0.128
Carotid IMT (mm) 0.217
Baseline 0.73±0.17 0.67±0.13
Study end  0.70±0.17 0.66±0.16
p 0.061 0.213
FMD (%) 0.088
Baseline 7.1±4.1 8.4±4.3
Study end  8.0±3.0 9.1±3.2
p 0.118 0.086
LVMI (g/m
2) 0.193
Baseline 126.3±26.80 124.2±24.30
Study end  116.7±25.30 130.6±41.60
p 0.018 0.781
SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: 
body mass index, HbA1c: glycosylated hemoglobin, FPG: fasting 
plasma glucose, FPI: fasting plasma insulin, HOMA: homeostasis 
assessment model of insulin resistance, TC: total cholesterol, TG: 
triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: 
low density lipoprotein-cholesterol, IL-6: interleukin-6, cfPWV: 
carotid-femoral pulse wave velocity, IMT: intima-media thickness, 
FMD: flow-mediated dilation, LVMI: left ventricular mass index588   Telmisartan Versus Valsartan in Hypertensive Patients
respectively, both of which were not significant after adjust-
ing for baseline cfPWV (Figs. 1 and 2). When we further ad-
justed BP changes and heart rate changes in addition to base-
line cfPWV, the mean (95% CI) difference in the cfPWV ch-
anges, 38.7 (-30.3, 107.7) cm/s, was also not significant (p= 
0.265).
Discussion
We compared the cardiovascular, metabolic, and anti-in-
flammatory effects of two ARB drugs, telmisartan and valsar-
tan, in a 12-week treatment trial in patients with uncompli-
cated hypertension. The systolic and diastolic BPs were sig-
nificantly reduced but none of the other study variables ch-
anged significantly in either group, except for cfPWV in the 
valsartan group. None of the changes in the measured cardio-
vascular, metabolic and inflammatory parameters were signi-
ficantly different between the two groups in the present study.
ARBs are preferred agents to prescribe for hypertension 
management in Korea
16) as well as in other countries. ARBs 
are a valuable alternative to ACEIs in contrast to ACEIs, which 
many patients, particularly women, Asians, and blacks, are un-
able to tolerate due to adverse side-effects. ARBS are highly 
effective first-line agents for reducing BP as well as providing 
cardiovascular and renal protection, and they have the cardi-
nal strength of improved, placebo-like tolerability and higher 
patient compliance rates compared with other drug classes.
17)
Although ARBs share a common mechanism of action, 
their molecular structures and pharmacological profiles vary. 
However, there is a lack of large, independent, direct com-
parative trials for drugs within the ARB class. 
Telmisartan is a compound that can simultaneously block 
RAS and activate PPARγ,
6)7) so it has the potential to treat 
both the hemodynamic and biochemical features of metabo-
lic syndrome such as hypertension, insulin resistance, and dy-
slipidemia. Benson et al.
6) recently reported that telmisartan 
could function as a partial PPARγ agonist, which could in-
fluence the expression of the PPARγ target genes involved in 
carbohydrate and lipid metabolism, whereas telmisartan re-
duces glucose, insulin, and triglyceride levels in rats fed a high-
fat, high-carbohydrate diet. They also reported that none of 
the other commercially available ARBs appeared to activate 
PPARγ when tested at concentrations typically achieved in 
the plasma with conventional oral dosing.
The ability to activate PPARγ in addition to blocking the 
RAS led us expect that some beneficial effects on insulin re-
sistance, lipid profiles, adiponectin, and IL-6 would be found 
in the telmisartan group. But, neither telmisartan nor valsar-
tan showed improvement in these indices. It might be because 
these indices are not significantly abnormal to fulfill the meta-
bolic syndrome criteria at baseline in our uncomplicated hy-
pertensive subjects and the treatment duration was too short 
to demonstrate significant changes. Nevertheless, trends for 
a reduction in total cholesterol (-4.7%, p=0.075) and triglycer-
ide (-5.6%, p=0.058) were observed in the telmisartan group.
Telmisartan is the longest acting ARB currently available, 
with a mean plasma half-life of approximately 24 hours, and 
it has a better BP trough-to-peak ratio in the range of 0.7-1.0 
in addition to having the largest distribution volume (500 L), 
the strongest binding affinity, and the longest duration of re-
ceptor blockade compared with other agents in this class. Tel-
misartan also has a rapid onset of action (maximum plasma 
concentrations are achieved 0.5-1.5 hours after administra-
tion).
17) Compared with losartan, telmisartan shows superior 
efficacy during the day-time, night-time, and last 6 hours of 
the dosage interval.
18) Moreover, using ambulatory BP moni-
toring, 80 mg telmisartan is superior to 160 mg valsartan in 
the last 6 hours of the dosing interval.
19) These features of tel-
misartan might have caused the significant reduction in the 
cfPWV from baseline, which represents aortic stiffness. But 
the reduction was marginally insignificant after adjusting for 
baseline cfPWV, which was significantly higher in the telmi-
sartan group, suggesting that the baseline level of aortic stiff-
ness may strongly affect the changes in cfPWV caused by an-
ti-hypertensive treatment. In contrast, the adjusted cfPWV de-
creased significantly from baseline in the valsartan group. Al-
though the mean reductions in BP were not significantly dif-
ferent between the two groups, slightly more of a reduction 
(1.7 and 0.6 mm Hg, systolic and diastolic, respectively) in the 
valsartan group may have affected the result. Because BP is 
one of the strongest influencing factors of aortic stiffness,
20) a 
reduction in cfPWV along with decreasing BP, even with a sh-
ort term follow-up, was not surprising.
21-23) However, the dif-
ference in the changes of the adjusted cfPWV from baseline 
was not significant between the two treatments (Fig. 1). 
Because the aorta is the first afterload interface for the left 
ventricle, LVMI should be significantly affected by aortic 
stiffness. Therefore, we also adjusted baseline cfPWV when 
we compared the changes in LVMI from baseline between the 
two groups. The adjusted changes in LVMI were not signifi-
cant in either group, and the difference in the LVMI changes 
between the two groups was also not significant, though it 
was favorable for the telmisartan group (Fig. 2). A 12-week 
ARB treatment may be insufficient to show a significant im-
provement in LVMI either by lowering the BP or by BP-inde-
pendent efficacy, such as the myocardial fibrosis regression 
demonstrated in experimental rat models
24)25) and patients 
with hypertension.
26)
Although changes in the other vascular indices, such as the 
carotid IMT and FMD, were not significant in either treat-
ment, a trend for a reduction in the carotid IMT (-3.7%, p= 
0.061) was observed in the telmisartan group.
This study had several potential limitations. First, the num-
ber of participating subjects was small, and the duration of tr-Sung Yoon Lim, et al.   589
eatment may have been insufficient to demonstrate overt dif-
ferences between the baseline and the end of the study and 
between the two groups. Because this study was designed as an 
open-labeled pilot study to prepare for a larger and longer 
prospective study, we believe the results must be interpreted 
with caution. Second, although we performed this study with 
a small number of patients, we evaluated LVMI using echo-
cardiography. Echocardiographic quantification of ventricu-
lar mass has been perceived as less reliable because of limited 
echocardiography standardization and because of its reliance 
on left ventricular wall thickness measurements and geo-
metric assumptions about the shape of the left ventricle.
27) If 
we had used cardiac magnetic resonance imaging, which is 
regarded as the current standard of reference for an accurate 
and reproducible in vivo measurement of left ventricular 
mass, the results may have been different with this small num-
ber of patients. But, we tried to reduce potential errors with re-
peated LVMI measurements. 
We conclude that the effects of a 12-week of treatment with 
two ARBs, telmisartan and valsartan, on the cardiovascular, 
metabolic and inflammatory parameters were not significant-
ly different in patients with uncomplicated hypertension.
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